Autologous engineered T cell receptor therapy in advanced cancer
ABSTRACTTo overcome challenges associated with adoptive cell therapy (ACT), we developed a personalized autologous T-cell therapy program. Patients with advanced cancer with HLA-A *02:01 allele and tumor expression of PRAME, MAGEA1, MAGEA4, MAGEA8, NY-ESO-1, COL6A3 exon 6, MXRA5, and/or MMP1 underwe...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2023.2290356 |
| _version_ | 1797351329771814912 |
|---|---|
| author | Apostolia M. Tsimberidou Mehmet A. Baysal Abhijit Chakraborty Borje S. Andersson |
| author_facet | Apostolia M. Tsimberidou Mehmet A. Baysal Abhijit Chakraborty Borje S. Andersson |
| author_sort | Apostolia M. Tsimberidou |
| collection | DOAJ |
| description | ABSTRACTTo overcome challenges associated with adoptive cell therapy (ACT), we developed a personalized autologous T-cell therapy program. Patients with advanced cancer with HLA-A *02:01 allele and tumor expression of PRAME, MAGEA1, MAGEA4, MAGEA8, NY-ESO-1, COL6A3 exon 6, MXRA5, and/or MMP1 underwent leukapheresis and T-cell product manufacturing. Patients received lymphodepletion, IMA101 infusion and interleukin 2 for 14 days. Of 214 screened patients, 14 were treated (6, IMA101; 8, IMA101 and atezolizumab). The most common adverse events were cytokine release syndrome (G1, n = 6; G2, n = 4) and cytopenia. At 6 weeks, 12 (85.7%) patients had stable disease. Three patients had prolonged disease stabilization for 12.9, 7.3, and 13.7 months, respectively. The median progression-free survival and overall survival were 3.4 months and 9.4 months, respectively. Target-specific T cells expanded to constitute up to 78.7% of CD8+ cells. In conclusion, IMA101 was feasible and well tolerated, leveraging the potential of multi-targeted ACT that warrants further investigation. |
| first_indexed | 2024-03-08T12:58:50Z |
| format | Article |
| id | doaj.art-feb043363ffc49cca62e71ac4fff02e9 |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-08T12:58:50Z |
| publishDate | 2023-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-feb043363ffc49cca62e71ac4fff02e92024-01-19T13:34:13ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2023-12-0119310.1080/21645515.2023.2290356Autologous engineered T cell receptor therapy in advanced cancerApostolia M. Tsimberidou0Mehmet A. Baysal1Abhijit Chakraborty2Borje S. Andersson3Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USADepartment of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USADepartment of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USADepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USAABSTRACTTo overcome challenges associated with adoptive cell therapy (ACT), we developed a personalized autologous T-cell therapy program. Patients with advanced cancer with HLA-A *02:01 allele and tumor expression of PRAME, MAGEA1, MAGEA4, MAGEA8, NY-ESO-1, COL6A3 exon 6, MXRA5, and/or MMP1 underwent leukapheresis and T-cell product manufacturing. Patients received lymphodepletion, IMA101 infusion and interleukin 2 for 14 days. Of 214 screened patients, 14 were treated (6, IMA101; 8, IMA101 and atezolizumab). The most common adverse events were cytokine release syndrome (G1, n = 6; G2, n = 4) and cytopenia. At 6 weeks, 12 (85.7%) patients had stable disease. Three patients had prolonged disease stabilization for 12.9, 7.3, and 13.7 months, respectively. The median progression-free survival and overall survival were 3.4 months and 9.4 months, respectively. Target-specific T cells expanded to constitute up to 78.7% of CD8+ cells. In conclusion, IMA101 was feasible and well tolerated, leveraging the potential of multi-targeted ACT that warrants further investigation.https://www.tandfonline.com/doi/10.1080/21645515.2023.2290356Multitargeted autologous T-cell therapylymphodepletionadvanced canceradoptive cell therapyACTT- cell nfusion |
| spellingShingle | Apostolia M. Tsimberidou Mehmet A. Baysal Abhijit Chakraborty Borje S. Andersson Autologous engineered T cell receptor therapy in advanced cancer Human Vaccines & Immunotherapeutics Multitargeted autologous T-cell therapy lymphodepletion advanced cancer adoptive cell therapy ACT T- cell nfusion |
| title | Autologous engineered T cell receptor therapy in advanced cancer |
| title_full | Autologous engineered T cell receptor therapy in advanced cancer |
| title_fullStr | Autologous engineered T cell receptor therapy in advanced cancer |
| title_full_unstemmed | Autologous engineered T cell receptor therapy in advanced cancer |
| title_short | Autologous engineered T cell receptor therapy in advanced cancer |
| title_sort | autologous engineered t cell receptor therapy in advanced cancer |
| topic | Multitargeted autologous T-cell therapy lymphodepletion advanced cancer adoptive cell therapy ACT T- cell nfusion |
| url | https://www.tandfonline.com/doi/10.1080/21645515.2023.2290356 |
| work_keys_str_mv | AT apostoliamtsimberidou autologousengineeredtcellreceptortherapyinadvancedcancer AT mehmetabaysal autologousengineeredtcellreceptortherapyinadvancedcancer AT abhijitchakraborty autologousengineeredtcellreceptortherapyinadvancedcancer AT borjesandersson autologousengineeredtcellreceptortherapyinadvancedcancer |